Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

13.05.2022 - Conference call scheduled for 8:30 a.m. ET todayMIAMI, May 13, 2022 (GLOBE NEWSWIRE) - Longeveron Inc. (NASDAQ: LGVN) ('Longeveron' or 'Company'), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and ...

Related Keywords

Nagoya ,Aichi ,Japan ,United States ,Canada ,Bluerock ,Nova Scotia ,Bahamas ,The ,Japanese ,Todd Girolamo ,Elsie Yau ,Vagelos College Of Physicians ,Caladrius Biosciences Inc ,Journal Of The Alzheimer Association ,Juntendo University Hospital Tokyo ,Rockefeller University ,Blood Institute ,National Center ,Merck Research Laboratories ,Forgiveness Of Paycheck Protection Program ,Drug Administration ,Longeveron Inc ,Columbia University ,Exchange Commission ,Corporate Development ,Weill Medical College Of Cornell University ,National Institute Of Health Heart ,Harvard College ,Columbia Business School ,Biochemical Sciences ,University Of Pennsylvania Law School ,Hypoplastic Left Heart Syndrome ,National Institute ,National Heart ,Rare Pediatric Disease ,Orphan Drug Designations ,United States Food ,Aging Frailty ,Japanese Aging Frailty Phase ,Juntendo University Hospital ,Lomecelb Phase ,Acute Respiratory Distress Syndrome ,Influenza Infection ,Chief Medical Officer ,Investigational New Drug ,New Drug Applications ,Clinical Development ,Enterin Inc ,Clinical Pharmacology ,Cerevel Therapeutics ,Senior Medical Director ,Merck Research ,Vagelos College ,Weill Medical College ,Interim Chief Executive Officer ,General Counsel ,Chief Legal Officer ,Senior Vice President ,Pennsylvania Law School ,Columbia Business ,First Quarter Ended March ,Bahamas Registry Trial ,Bahamas Registry ,Dial In Number ,Replay Dial In Number ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Paycheck Protection Program ,